Business Wire

Rebrandly Announces Strategic Partnership with Nova Registry

Share

Today, branded link management platform, Rebrandly, announced a partnership with Nova Registry, operator of the .link generic Top Level Domain (gTLD). Under the terms of the agreement, registrar partners of Nova Registry will be able to offer .link names combined with Rebrandly's powerful link management capabilities.

With this partnership, Rebrandly and Nova Registry are committed to making it easy for creators to generate and manage branded links while amplifying the availability of the new .link TLD. By combining the .link TLD and Rebrandly’s suite of link management tools, businesses of all sizes will be better able to control their branding online and measure the performance of their linked assets.

“At Rebrandly, we’re focused on giving our customers the tools they need to fully brand, own and manage their links,” noted Rebrandly CEO, Carla Bourque. “We’re happy to partner with Nova Registry to bring our industry-leading capabilities to their registrar partners.”

In addition to providing customers private link analytics, Rebrandly links are also reusable - users can easily redirect, revise or remove linked content without changing the text. This combination of branded trust and easy editability make Rebrandly a rising leader in the link management industry. Nova Registry was founded by a collective of tech entrepreneurs and domain industry professionals who are on a mission to make the .link TLD the de facto standard for links and link management.

"We are excited to partner with Rebrandly to offer our registrar partners an integrated solution for creating and managing .link domains," said Nova Registry General Manager Vaughn Liley. "This partnership will provide our customers with a competitive edge in the marketplace and help them better manage and measure their link performance."

For more information on Rebrandly, please visit https://www.rebrandly.com. For additional information about .link, please visit https://nova.link/.

About Rebrandly

Rebrandly is a link management platform that allows users to securely brand, analyze and share custom URLs via a suite of industry-leading link solutions, including ClickMeter, Rebrandly, and LinkGallery. Rebrandly increases brand awareness, improves conversion rates, and tracks advanced analytics, helping companies of all sizes securely manage and measure their link engagement. Founded in 2015, and headquartered in the US, Rebrandly serves tens of thousands of organizations worldwide, including Delta Airlines, Land Rover, and Zillow. For more information, visit https://www.rebrandly.com.

About Nova Registry

Nova Registry Ltd. is the Registry Operator for the .link generic top-level domain, based in Valletta, Malta. The company is on a mission to link the world by making .link the de facto standard for all things link-related. From websites to link in bios, from branded links to the creator economy, from apps and wallets to emerging web3 technologies. Universally understood and without limits, .link enables users to create unforgettable identities. Memorable. Shareable. Brandable.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Ashley Mann, Pinegrove PR for Rebrandly
ashley@pinegrovepr.com
206.300.9891

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 10:15:00 EEST | Press release

Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i

Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 10:00:00 EEST | Press release

Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vice President, Skechers Technical Performance Division. “An evolution of our legacy in running, Skechers AERO was d

The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 10:00:00 EEST | Press release

Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP and Optical Transport, Mobile Networks, Mobile Services, and Data Centres. “Network X is more than a conference—it

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 08:00:00 EEST | Press release

4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. “Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,” said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. “Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. B

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 20:06:00 EEST | Press release

Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The company’s global headquarters includes WPC certified test equipment and state-of-the-art test labs dedicated to full product lifecycle validatio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye